Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.

International journal of hematology - 1 Aug 2024

Oya Shuki, Ozawa Hidetoshi, Nakamura Takayuki, Mori Akira, Ochi Sorahiko, Maehiro Yoshimi, Umeda Masahiro, Takaki Yusuke, Fukuyama Toshinobu, Yamasaki Yoshitaka, Yamaguchi Maki, Aoyama Kazutoshi, Mouri Fumihiko, Nagafuji Koji

Abstract excerpt

The single-nucleotide polymorphism (SNP) rs12459419 is located at the intron/exon junction of CD33 exon2. When exon2 is skipped by this CD33 SNP, the full-length CD33 (CD33FL) is converted to a short CD33 isoform (CD33D2). Since gemtuzumab ozogamicin (GO) only recognizes CD33FL, the CD33 SNP may affect the clinical efficacy of GO. To elucidate the significance of CD33 SNP on GO reactivity, we leveraged the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Gene Editing

Share to Leukemia, Myeloid, Acute

Share to Polymorphism, Single Nucleotide

Share to Sialic Acid Binding Ig-like Lectin 3

Source

Identifiers

PMID: 38853211
DOI: 10.1007/s12185-024-03803-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.PMID 38853211Read ↗

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Semantic proximity Read ↗

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agentsSemantic proximity Read ↗

Gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.Semantic proximity Read ↗

Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin.Semantic proximity Read ↗

Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy.Semantic proximity Read ↗

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin.Semantic proximity Read ↗

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot studySemantic proximity Read ↗

CD33 Epitope Editing Unlocks UM171-Expanded Cord Blood Grafts for AML ImmunotherapySemantic proximity Read ↗

Pseudogene-mediated gene conversion after CRISPR-Cas9 editing demonstrated by partial <i>CD33</i> conversion with <i>SIGLEC22P</i>Semantic proximity Read ↗

Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.Semantic proximity Read ↗

Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.